Pat O’Flynn
PAT O’FLYNN’S iron-absorption supplements company Solvotrin Therapeutics continues to attract the big bucks, with a business expansion scheme (BES) fund the latest to come on board here to join the stellar line up of existing investors. In total, €4m has been raised in this latest round at €250 a share, with €2.1m chucked in by... Read more »
To access this content, you must be a Phoenix subscriber.
Get access to The Phoenix online for as low as €1.50 per week. Read all the regular online only Phoenix stories AND receive the packed digital edition every fortnight (25 per year). Great value for so many inside stories!
